FDA approved Janssen Biotech’s Tremfya (guselkumab) for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Health insurer Anthem Inc. filed a lawsuit against Insys Therapeutics Inc., alleging the drugmaker fraudulently obtained reimbursements for its opioid painkiller Subsys.
From the leaders of marketing teams to medical affairs, pharma executives are increasingly required to do more with less. While this is true across industries, the U.S. biopharma industry is faced with unique headwinds.
FDA Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab
Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee recommended approval of the companies’ proposed biosimilar trastuzumab.
More than 400 people – including doctors and nurses – have been charged with defrauding Medicare and other federal healthcare programs of $1.3 billion, with many accused of illegally distributing opioids and other narcotics, the Justice Department said.
From the latest in VR to imaginative Social Engagement approaches, here are Ben Putman’s Top Five Digital Marketing takeaways for 2017.
A recent article in the New York Times, headlined Netflix Lets Viewers Pick the Plot, tells how the video streaming behemoth is creating content with an interactive twist.
Senate Republican leaders, aiming to salvage efforts backed by President Donald Trump to dismantle the Obamacare law, unveiled revised healthcare legislation that lets insurers sell bare-bones policies and retains key taxes on the wealthy.
A U.S. judge increased the amount medical device maker Zimmer Biomet Holdings Inc. must pay Stryker Corp. for infringing patents on a surgical cleaning wand to $248.7 million following a ruling by the U.S. Supreme Court.
Pfizer Announces FDA Accepts Supplemental New Drug Application for Xeljanz for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
Pfizer Inc. announced that the supplemental New Drug Application for Xeljanz (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative colitis, has been accepted for filing by the U.S. Food and Drug Administration.